Page 6 - 2020 ASCO-GU Canadian Ambassador Program
P. 6
CONTENT – PROSTATE CANCER
TOPICS
Abstract 9: A prospective phase II/III multicenter study of PSMA-targeted 18F-DCFPyL
PET/CT imaging in patients with prostate cancer (OSPREY): A sub-analysis of regional and
distant metastases detection rates at initial staging by 18F-DCFPyL PET/CT.
Abstract 10: Surveillance or metastasis-directed therapy for oligometastatic prostate
cancer recurrence (STOMP): Five-year results of a randomized phase II trial.
Abstract 276: Transcriptome profiling of NRG Oncology/RTOG 9601: Validation of a
prognostic genomic classifier in salvage radiotherapy prostate cancer patients from a
prospective randomized trial.
Abstract 82: Time to second progression (PFS2) in patients (pts) from TITAN with
metastatic castration-sensitive prostate cancer (mCSPC) by first subsequent therapy
(hormonal vs. taxane).
Abstract 162: Luminal B subtype as a predictive biomarker of docetaxel benefit for newly
diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A correlative study of
E3805 CHAARTED.
